Companies · Pharmaceuticals

Gate Science Inc.

MOULTONBOROUGH · Pharmaceuticals

Diligence memoA one-page analyst read on Gate Science Inc. — recommendation, valuation, rhythm, risks.
$2.6M
Total raised · real
3
Rounds
0.1×
Latest step-up
Top 70%
Sector rank · raised
Seed
Latest stage · inferred · Fri Nov 18 2022 00:00:00 GMT+0000 (Coordinated Universal Time)

Gate Science Inc. looks under-valued against its niche peers and is at-risk on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.17× the median modeled value of Seed Pharmaceuticals companies in 2022–2024 (50 peers) — value vs value, same stage and era.
At-risk
  • Last raise 3.6 yr ago; this sector typically re-raises about every 13 months.
  • Past due for a raise versus sector cadence — watch for distress or a bridge.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

Gate Science Inc. is one of 1610 Pharmaceuticals companies tracked from MOULTONBOROUGH. By capital raised it ranks in the long tail (ahead of 31% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
3
Investors (latest)
2020
Year incorporated
2022-11-18
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$13M$25M$38M$50MSeed · 2020-10-15 Raised $1.4M (real) Modeled valuation $47M (est)$1.4M$47MSeed2020Seed · 2021-04-15 Raised $1.1M (real) Modeled valuation $26M (est)$1.1M$26MSeed2021Seed · 2022-11-18 Raised $150K (real) Modeled valuation $1.7M (est)$150K$1.7MSeed2022+$1.1M+$150KCumulative $2.6M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$1.4M · 2020
Seed extension$1.1M · 2021
Seed extension$150K · 2022

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$1.7M
Base estimate est.
$113K
Conservative case
$6.8M
Upside case
$750K
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Seeda $1.0M–$4.0M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Seed · modeled $47.0M · 2020-10-152020Seed · modeled $26.5M · 2021-04-15Seed · modeled $1.7M · 2022-11-182022
Model inputs · modeled:benchmark-stage-stepup-v1
20%
Dilution assumption
Implied ownership sold in the financing.
34%
Survival probability
15% low · 52% high
1.68×/yr
Annual markup
2.20×/yr upside case
3.6 yr
Elapsed time used
3.6 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
13 mo
Avg between rounds
$1.3M/yr
Capital velocity
5.7 yr
On record since
2020
First round
3
Rounds on file
How it compares to the market

Benchmarked against 1610 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.3× of median
This company$2.6M
Sector median$8.1M
Latest round — vs other Seed rounds in sector (real $, this stage) 0.1× of median
This company$150K
Sector median$1.7M
Modeled value — vs sector median (estimate, all stages) 0.0× of median
This company$1.7M
Sector median$76.1M

Raised more than 31% of sector peers (real $). Modeled value above 4% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #45 of 50.

This companyCohort peer
$1.0M$10.0M$100.0M$1.0M$10.0MCapital raised (log)Celeris Therapeutics, Inc. · Seed Raised $3.0M · modeled $48.6M (est)Oligomerix, Inc. · Seed Raised $8.3M · modeled $37.8M (est)2A Biosciences, Inc. · Seed Raised $3.8M · modeled $36.0M (est)Myosin Therapeutics Inc. · Seed Raised $3.0M · modeled $32.4M (est)Eluciderm Inc. · Seed Raised $3.8M · modeled $31.7M (est)AION Healthspan, Inc. · Seed Raised $2.9M · modeled $28.5M (est)Cannabinoid API Solutions, LLC · Seed Raised $2.2M · modeled $27.4M (est)CanaQuest Medical Corp. · Seed Raised $2.0M · modeled $22.8M (est)M Chest Institutional Pharmacy Group, LLC · Seed Raised $3.7M · modeled $21.4M (est)Vitalis Therapeutics, Inc. · Seed Raised $2.0M · modeled $20.8M (est)Visiox Pharma, LLC · Seed Raised $1.3M · modeled $17.5M (est)Adtech Pharma, Inc. · Seed Raised $3.0M · modeled $16.9M (est)Gate Science Inc. (this company) Raised $2.6M · modeled $1.7M (est)Gate Science Inc.
CompanyStageRaised · realValue · estvs peer med.
Celeris Therapeutics, Inc.Seed$3.0M$48.6M5.06×
Oligomerix, Inc.Seed$8.3M$37.8M3.93×
2A Biosciences, Inc.Seed$3.8M$36.0M3.74×
Myosin Therapeutics Inc.Seed$3.0M$32.4M3.37×
Eluciderm Inc.Seed$3.8M$31.7M3.29×
AION Healthspan, Inc.Seed$2.9M$28.5M2.96×
Cannabinoid API Solutions, LLCSeed$2.2M$27.4M2.85×
CanaQuest Medical Corp.Seed$2.0M$22.8M2.37×
M Chest Institutional Pharmacy Group, LLCSeed$3.7M$21.4M2.22×
Vitalis Therapeutics, Inc.Seed$2.0M$20.8M2.16×
Visiox Pharma, LLCSeed$1.3M$17.5M1.82×
Adtech Pharma, Inc.Seed$3.0M$16.9M1.76×
Gate Science Inc. this companySeed$2.6M$1.7M0.17×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$1.4M2020-10-15$7.2M$47.0M90%
Seed$1.1M2021-04-15$5.3M$26.5M90%
Seed$150K2022-11-18$750K$1.7M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$1.4M2020-10-15
    • First recorded raise — entered as Seed.
    • 13 investors on this round.
  2. Seed$1.1M2021-04-15
    • Came back fast: 6 mo vs the ~13 mo sector norm.
    • Round 1.4× smaller than the prior — bridge or down round.
    • 6 investors on this round.
  3. Seed$150K2022-11-18
    • Raised 19 mo later, in step with the ~13 mo sector norm.
    • Round 7.0× smaller than the prior — bridge or down round.
    • 3 investors on this round.
Intelligence
2023 ~Q4
Modeled next raise · ~13mo cadence
$150K
Modeled next size est.range $150K$240K
0.1×
Last step-up
$1.3M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
NEIL BODICK1 other2020-10
Lara Wynne2020-10
Phillip Reilly2020-10
Sanjay Sinha2020-10
William Suter2020-10
Registry & provenance

Gate Science Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1829573
SEC CIK
2020
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Doza Investments - Relox Medical, L.P.PharmaceuticalsSeed$2.7M$4.5Msame sector · same stage
TheraVasc Inc.PharmaceuticalsSeed$2.6M$13.3Msame sector · same stage
Xtresse, LlcPharmaceuticalsSeed$2.7M$6.5Msame sector · same stage
Aclipse Therapeutics LLCPharmaceuticalsSeed$2.5M$4.2Msame sector · same stage
Nomocan Pharmaceuticals LlcPharmaceuticalsSeed$2.7M$3.4Msame sector · same stage
Earth Science Tech, Inc.PharmaceuticalsSeed$2.8M$7.8Msame sector · same stage
ImmunoPrecise Antibodies Ltd.PharmaceuticalsSeed$2.5M$9.3Msame sector · same stage
Mayne Pharma Group LtdPharmaceuticalsSeed$2.8M$5.4Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Gate Neurosciences, Inc.PharmaceuticalsSeries A$247.9M92%
Eyegate Pharmaceuticals IncPharmaceuticalsSeries A$92.5M82%
Earth Science Tech, Inc.PharmaceuticalsSeed$7.8M82%
Gatehouse Bio, Inc.BiotechnologySeries A$154.5M81%
Gate Labs Inc.Software / TechSeries A$84.5M80%
Silvergate Pharmaceuticals, Inc.PharmaceuticalsSeries B$156.4M80%
Navigator Medicines, Inc.BiotechnologySeries C$421.6M79%
Enveric Biosciences, Inc.PharmaceuticalsSeries A$3.7M79%
Frequently asked
How much funding has Gate Science Inc. raised?
Gate Science Inc. has raised approximately $2.6M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Gate Science Inc.'s estimated valuation?
Provath's modeled valuation for Gate Science Inc. is approximately $1.7M (modeled range $113K–$6.8M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Gate Science Inc. at?
Gate Science Inc.'s latest modeled financing stage is Seed. Its most recent recorded round closed around Fri Nov 18.
What does Gate Science Inc. do and where is it based?
Gate Science Inc. operates in the Pharmaceuticals sector, based in MOULTONBOROUGH.
Explore related

See where Gate Science Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Gate Science Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.